Phage nanofibers in nanomedicine: Biopanning for early diagnosis, targeted therapy, and proteomics analysis

Xu, Hong; Cao, Binrui; Li, Yan; Mao, Chuanbin

doi:10.1002/wnan.1623

Cited by 17 publications

(11 citation statements)

References 301 publications

(314 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alterations in oral cavity bacterial microbiota to more pathogenic microbes in addition to known etiological factors, smoking, and alcohol consumption contribute to oral carcinogenesis [151]. Thanks to the achievements of future research, there might be possibilities to manage known possibly carcinogenic bacteria with personalized medicine, such as phage therapy [152, 153]. In the meantime, mechanical biofilm disruption and good oral hygiene are essential in preventing harmful bacteria from colonizing the oral cavity.…”

Section: Discussionmentioning

confidence: 99%

Oral Microbiota and Cancer Development

2020

View full text Add to dashboard Cite

Oral microbiota are among the most diverse in the human body. More than 700 species have been identified in the mouth, and new sequencing methods are allowing us to discover even more species. The anatomy of the oral cavity is different from that of other body sites. The oral cavity has mucosal surfaces (the tongue, the buccal mucosa, the gingiva, and the palate), hard tissues (the teeth), and exocrine gland tissue (major and minor salivary glands), all of which present unique features for microbiota composition. The connection between oral microbiota and diseases of the human body has been under intensive research in the past years. Furthermore, oral microbiota have been associated with cancer development. Patients suffering from periodontitis, a common advanced gingival disease caused by bacterial dysbiosis, have a 2–5 times higher risk of acquiring any cancer compared to healthy individuals. Some oral taxa, especially <i>Porphyromonas gingivalis</i> and <i>Fusobacterium nucleatum</i>, have been shown to have carcinogenic potential by several different mechanisms. They can inhibit apoptosis, activate cell proliferation, promote cellular invasion, induce chronic inflammation, and directly produce carcinogens. These microbiota changes can already be seen with potentially malignant lesions of the oral cavity. The causal relationship between microbiota and cancer is complex. It is difficult to accurately study the impact of specific bacteria on carcinoma development in humans. This review focuses on the elucidating the interactions between oral cavity bacterial microbiota and cancer. We gather literature on the current knowledge of the bacterial contribution to cancer development and the mechanisms behind it.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral Microbiota and Cancer Development

2020

View full text Add to dashboard Cite

show abstract

“…[ 69 , 70 , 101 , 102 , 103 , 104 , 105 ] Phage libraries could be applied for selecting polypeptides that bind to fixed proteins, [ 106 , 107 , 108 , 109 ] carbohydrates, nanoparticles, [ 110 ] cells, [ 111 ] and tissue. [ 112 , 113 , 114 ] In vitro biopanning methods using T7 bacteriophages to obtain specific affinity polypeptides, [ 41 , 42 ] proteins [ 40 ] or antibodies [ 115 ] have several advantages such as high efficiency, low cost, and simple operation. [ 116 ] In vivo biopanning techniques are proved significant to identify cell‐ or tissue‐affinity addresses.…”

Section: Theranostic Use Of T7 Phagementioning

confidence: 99%

T7 Phage as an Emerging Nanobiomaterial with Genetically Tunable Target Specificity

Hui

Yang

et al. 2021

Advanced Science

Self Cite

View full text Add to dashboard Cite

Bacteriophages, also known as phages, are specific antagonists against bacteria. T7 phage has drawn massive attention in precision medicine owing to its distinctive advantages, such as short replication cycle, ease in displaying peptides and proteins, high stability and cloning efficiency, facile manipulation, and convenient storage. By introducing foreign gene into phage DNA, T7 phage can present foreign peptides or proteins site-specifically on its capsid, enabling it to become a nanoparticle that can be genetically engineered to screen and display a peptide or protein capable of recognizing a specific target with high affinity. This review critically introduces the biomedical use of T7 phage, ranging from the detection of serological biomarkers and bacterial pathogens, recognition of cells or tissues with high affinity, design of gene vectors or vaccines, to targeted therapy of different challenging diseases (e.g., bacterial infection, cancer, neurodegenerative disease, inflammatory disease, and foot-mouth disease). It also discusses perspectives and challenges in exploring T7 phage, including the understanding of its interactions with human body, assembly into scaffolds for tissue regeneration, integration with genome editing, and theranostic use in clinics. As a genetically modifiable biological nanoparticle, T7 phage holds promise as biomedical imaging probes, therapeutic agents, drug and gene carriers, and detection tools.

show abstract

“…As alluded to in previous sections, surface functionalisation with ligands such as CBSA, transferrin and glutathione or peptides such as RGD have generated potentially useful active-targeted nanocarriers for receptor-mediated transport across the BBB. However, in numerous instances, it is becoming increasingly clear that the advent of new technologies such as phage display [232] means that cell-derived nanoparticles have unrealised possibilities for advanced drug delivery to the CNS.…”

Section: Unrealised Promise Of Biomaterial-inspired Rational Ntp Designmentioning

confidence: 99%

Advances in Non-Animal Testing Approaches towards Accelerated Clinical Translation of Novel Nanotheranostic Therapeutics for Central Nervous System Disorders

Lynch

Gobbo

2021

Nanomaterials

View full text Add to dashboard Cite

Nanotheranostics constitute a novel drug delivery system approach to improving systemic, brain-targeted delivery of diagnostic imaging agents and pharmacological moieties in one rational carrier platform. While there have been notable successes in this field, currently, the clinical translation of such delivery systems for the treatment of neurological disorders has been limited by the inadequacy of correlating in vitro and in vivo data on blood–brain barrier (BBB) permeation and biocompatibility of nanomaterials. This review aims to identify the most contemporary non-invasive approaches for BBB crossing using nanotheranostics as a novel drug delivery strategy and current non-animal-based models for assessing the safety and efficiency of such formulations. This review will also address current and future directions of select in vitro models for reducing the cumbersome and laborious mandate for testing exclusively in animals. It is hoped these non-animal-based modelling approaches will facilitate researchers in optimising promising multifunctional nanocarriers with a view to accelerating clinical testing and authorisation applications. By rational design and appropriate selection of characterised and validated models, ranging from monolayer cell cultures to organ-on-chip microfluidics, promising nanotheranostic particles with modular and rational design can be screened in high-throughput models with robust predictive power. Thus, this article serves to highlight abbreviated research and development possibilities with clinical translational relevance for developing novel nanomaterial-based neuropharmaceuticals for therapy in CNS disorders. By generating predictive data for prospective nanomedicines using validated in vitro models for supporting clinical applications in lieu of requiring extensive use of in vivo animal models that have notable limitations, it is hoped that there will be a burgeoning in the nanotherapy of CNS disorders by virtue of accelerated lead identification through screening, optimisation through rational design for brain-targeted delivery across the BBB and clinical testing and approval using fewer animals. Additionally, by using models with tissue of human origin, reproducible therapeutically relevant nanomedicine delivery and individualised therapy can be realised.

show abstract

Phage nanofibers in nanomedicine: Biopanning for early diagnosis, targeted therapy, and proteomics analysis

Cited by 17 publications

References 301 publications

Oral Microbiota and Cancer Development

Oral Microbiota and Cancer Development

T7 Phage as an Emerging Nanobiomaterial with Genetically Tunable Target Specificity

Advances in Non-Animal Testing Approaches towards Accelerated Clinical Translation of Novel Nanotheranostic Therapeutics for Central Nervous System Disorders

Contact Info

Product

Resources

About